On June 30, 2025, Entero Therapeutics, Inc. held its Annual Meeting where stockholders elected five directors, approved a reverse stock split (1:2 to 1:20), and ratified the appointment of an accounting firm. The proposals received majority support, indicating strong investor engagement.